Adhoc: Relief Therapeutics Holding SA: Relief Reports Half-Year 2022 Results and Provides Corporate Update

Relief Therapeutics Holding SA / Key word(s): Interim Report Relief Reports Half-Year 2022 Results and Provides Corporate Update 15-Sep-2022 / 07:00 CET/CEST Release of an ad hoc announcement pursuant

Related Keywords

Geneva ,Genè ,Switzerland ,Secheron ,Switzerland General ,United States ,United Kingdom ,Swiss ,Christopher Wick ,Anthony Kim ,Michael Miller ,Advita Lifescience Gmbh ,Jack Weinstein ,Raghuram Selvaraju ,David Mccullough ,Relief Therapeutics Holding Sa Key ,Rx Communications Group ,Meta Healthcare Ltd ,Nasdaq ,Nasdaq Stock Exchange ,Swiss Exchange Listing ,Acer Therapeutics Inc ,News Service ,Pharma Research ,European Commission ,Swiss Exchange ,Nrx Pharmaceuticals ,Exchange Commission ,Swiss Financial Services ,Key Clinical Development ,International Journal Of Molecular Sciences ,Relief Therapeutics Holding ,Securities Exchange ,Neurorx Inc ,Swiss Patent Office ,Reports Half Year ,Provides Corporate Update ,Provides Corporate ,Executive Director ,Drew Cronin Fine ,Senior Director ,Senior Vice President ,Meta Healthcare ,Acer Therapeutics ,New Drug Application ,Prescription Drug User Fee Act ,Marketing Authorization Application ,Investigational New Drug ,Maple Syrup Urine Disease ,Orphan Drug Designation ,Nasdaq Stock Market ,Clinical Development Highlights ,International Journal ,Molecular Sciences ,Patent Application ,Complete Response Letter ,United Kingdom Based ,Intestinal Peptide ,Drug Induced Pneumonitis ,Use Diclofenac Packs ,Serene Forte ,Genetic Medicine ,Registration Statement ,Securities Exchange Act ,Securities Act ,American Depositary Shares ,Nasdaq Stock ,Six Months Ended June ,License Agreement ,Urea Cycle Disorders ,Financial Officer ,Communications Group ,Swiss Financial Services Act ,Exchange Listing ,Adhoc ,Relief ,Herapeutics ,Molding ,Reports ,Calf ,Ear ,022 ,Results ,Rovides ,Corporate ,Update ,